End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 AUD | +12.50% | +5.88% | -10.00% |
Apr. 30 | Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024 | |
Apr. 10 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
Sales 2024 * | 11.6M 7.63M | Sales 2025 * | 3.6M 2.37M | Capitalization | 21.49M 14.14M |
---|---|---|---|---|---|
Net income 2024 * | -8M -5.26M | Net income 2025 * | -13M -8.55M | EV / Sales 2024 * | 1.23 x |
Net cash position 2024 * | 7.2M 4.74M | Net cash position 2025 * | 9.2M 6.05M | EV / Sales 2025 * | 3.41 x |
P/E ratio 2024 * |
-1.64
x | P/E ratio 2025 * |
-2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.58% |
Latest transcript on Syntara Limited
1 day | +12.50% | ||
1 week | +5.88% | ||
Current month | +12.50% | ||
3 months | -14.29% | ||
6 months | -40.00% | ||
Current year | -10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Gary Phillips
CEO | Chief Executive Officer | 62 | 03-03-11 |
Director of Finance/CFO | 67 | 02-11-30 | |
Jana Baskar
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
CEO | Chief Executive Officer | 62 | 03-03-11 |
Director of Finance/CFO | 67 | 02-11-30 | |
Kathleen Metters
CHM | Chairman | 66 | 17-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 0.018 | +12.50% | 3,390,131 |
24-05-07 | 0.016 | 0.00% | 390,299 |
24-05-06 | 0.016 | +6.67% | 172,688 |
24-05-03 | 0.015 | 0.00% | 1,798,410 |
24-05-02 | 0.015 | -11.76% | 1,245,708 |
End-of-day quote Australian S.E., May 07, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.00% | 14.13M | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+16.00% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- SNT Stock